We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors
Read MoreHide Full Article
Lexington, MA-based immuno-oncology company Agenus Inc. (AGEN - Free Report) announced that it has dosed the first patient in a phase I/II study on INCAGN1949 for the treatment of patients with solid tumors.
The open-label, dose-escalation part of the study will evaluate the safety and tolerability of INCAGN1949 in patients with advanced or metastatic solid tumors. This part will also determine the pharmacologically active and/or maximum tolerated dose.
On the other hand, part II of the study will evaluate the recommended dose of INCAGN1949 in multiple tumor types.
Note that INCAGN1949, an anti-OX40 agonist antibody, is being developed in collaboration with Incyte Corporation (INCY - Free Report) . The companies entered into a global alliance in Jan 2015 to discover, develop and commercialize immuno-therapeutics using Agenus’ antibody platforms.
Under the collaboration with Incyte, Agenus is also evaluating an anti-GITR checkpoint antibody – INCAGN1876 – in a phase I/II study for the treatment of solid tumors. In addition, the companies are studying an anti-CTLA-4 antibody – AGEN1884 – in a phase I study for solid tumors.
Meanwhile, Agenus plans to initiate a phase I study on its second anti-CTLA-4 antibody, AGEN2041 in 2017. Moreover, the company’s PD-1 antagonist, AGEN2034, is expected to enter the clinic in the first quarter of 2017. Also, Agenus expects to begin combination studies on AGEN2034 and AGEN1884 for the treatment of second-line tumors in the second half of 2017.
A look at Agenus’ year-to-date share price movement shows that the stock has dropped 9.3% compared to the 23.2% decline for the Zacks categorized Medical/Biomedical Genetics industry.
Zacks Rank & Key Picks
Agenus currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include Cambrex Corporation and Vanda Pharmaceuticals, Inc. (VNDA - Free Report) . Both stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cambrex’s earnings estimates increased from $2.46 to $2.55 for 2016 and from $2.91 to $3.06 for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19.78%.
Vanda’s loss estimates narrowed from 68 cents to 56 cents for 2016, while its earnings estimates increased from 16 cents to 17 cents for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average positive surprise of 56.65%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors
Lexington, MA-based immuno-oncology company Agenus Inc. (AGEN - Free Report) announced that it has dosed the first patient in a phase I/II study on INCAGN1949 for the treatment of patients with solid tumors.
The open-label, dose-escalation part of the study will evaluate the safety and tolerability of INCAGN1949 in patients with advanced or metastatic solid tumors. This part will also determine the pharmacologically active and/or maximum tolerated dose.
On the other hand, part II of the study will evaluate the recommended dose of INCAGN1949 in multiple tumor types.
Note that INCAGN1949, an anti-OX40 agonist antibody, is being developed in collaboration with Incyte Corporation (INCY - Free Report) . The companies entered into a global alliance in Jan 2015 to discover, develop and commercialize immuno-therapeutics using Agenus’ antibody platforms.
Under the collaboration with Incyte, Agenus is also evaluating an anti-GITR checkpoint antibody – INCAGN1876 – in a phase I/II study for the treatment of solid tumors. In addition, the companies are studying an anti-CTLA-4 antibody – AGEN1884 – in a phase I study for solid tumors.
Meanwhile, Agenus plans to initiate a phase I study on its second anti-CTLA-4 antibody, AGEN2041 in 2017. Moreover, the company’s PD-1 antagonist, AGEN2034, is expected to enter the clinic in the first quarter of 2017. Also, Agenus expects to begin combination studies on AGEN2034 and AGEN1884 for the treatment of second-line tumors in the second half of 2017.
AGENUS INC Price
AGENUS INC Price | AGENUS INC Quote
A look at Agenus’ year-to-date share price movement shows that the stock has dropped 9.3% compared to the 23.2% decline for the Zacks categorized Medical/Biomedical Genetics industry.
Zacks Rank & Key Picks
Agenus currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include Cambrex Corporation and Vanda Pharmaceuticals, Inc. (VNDA - Free Report) . Both stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cambrex’s earnings estimates increased from $2.46 to $2.55 for 2016 and from $2.91 to $3.06 for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19.78%.
Vanda’s loss estimates narrowed from 68 cents to 56 cents for 2016, while its earnings estimates increased from 16 cents to 17 cents for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average positive surprise of 56.65%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>